Shir Grunebaum
Biographic Data
| ID | 9570805 |
|---|---|
| NAME | Shir Grunebaum |
| GIVEN NAMES | Shir |
| FAMILY NAME | Grunebaum |
| SIGNATURE | GRUNEBAUM S |
| AFFILIATIONS | York University |
| ORCID | 0009-0001-9926-457X |
| VERIFIED | Yes |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2024 |
| LATEST PUBLICATION YEAR | 2024 |
| H-INDEX | 0 |
Lessons learned from the Canadian Fabry Disease Initiative for future risk-sharing and managed access agreements for pharmaceutical and advanced therapies in Canada
Risk sharing agreements (RSAs) and managed access agreements have emerged as tools to overcome evidentiary uncertainty and contain costs of pharmaceuticals; however, Canada has relatively little experience with these health policy instruments. This article describes one of the few examples of national RSAs. Enzyme replacement therapies (ERT) were introduced in Canada to treat Fabry disease in the early 2000s through an RSA. Based on qualitative i…
No prominent works on this page.
Lessons learned from the Canadian Fabry Disease Initiative for future risk-sharing and managed access agreements for pharmaceutical and advanced therapies in Canada
Risk sharing agreements (RSAs) and managed access agreements have emerged as tools to overcome evidentiary uncertainty and contain costs of pharmaceuticals; however, Canada has relatively little experience with these health policy instruments. This article describes one of the few examples of national RSAs. Enzyme replacement therapies (ERT) were introduced in Canada to treat Fabry disease in the early 2000s through an RSA. Based on qualitative i…
Business (1 work) · Corporate governance (1 work) · Disease (1 work) · Fabry disease (1 work) · Finance (1 work) · Health Systems, Economic Evaluations, Quality of Life (1 work) · Inequality (1 work) · Lysosomal Storage Disorders Research (1 work) · Medicine (1 work) · Pharmaceutical Economics and Policy (1 work)